Paul Belmonte, C-Path’s Scientific Director, T1D Consortium, and Luke Kosinski, Director, Quantitative Medicine, will present a poster titled “Development of a Tool to Optimize Clinical Trial Design in New-Onset T1D” at the 20th Immunology of Diabetes Society (IDS) Congress on Tuesday, November 5, from 5:30-7:00 pm CET in Balcony 1+2 at the Concertgebouw event venue located in Bruges.
This poster will highlight C-Path’s efforts to develop a regulatory-grade clinical trial simulation tool to inform trial design in new onset T1D, using a drug-disease trial model measuring C-peptide area under the curve (AUC) during the 2-hour mixed-meal tolerance test (MMTT). This tool will be made publicly available in December.
The IDS Congress is the reference conference on pathogenesis, prediction, prevention and cure of Type 1 Diabetes, organized by the IDS and a local institution every 18 months. IDS unites the key players in the T1D field worldwide. The upcoming 20th IDS conference will take place in the old city of Bruges, Belgium, hosted by Prof. Chantal Mathieu and Dr. Lut Overbergh from KU Leuven (Belgium).
For more information on the event: https://idsbruges2024.com/
Founded in 2017, the T1D Consortium (T1DC) works to achieve regulatory endorsement of Clinical Trial Simulation Tools (CTST) in both new-onset and prevention of T1D to improve clinical trial design, accelerate development of new therapies, and positively impact the entire T1D community.
For more information on the T1DC: https://c-path.org/program/type-1-diabetes-consortium/
